Roche Pegasys
Pegylated interferon for hepatitis C receives "complete response" letter from FDA April 10. Outstanding issues are not related to safety or efficacy, Roche says
Pegylated interferon for hepatitis C receives "complete response" letter from FDA April 10. Outstanding issues are not related to safety or efficacy, Roche says